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Introduction {#sec1}
============

Hematopoiesis is thought to begin from stem cells that progress through consecutive precursor cell stages in a hierarchical fashion whereby lineage commitment precludes alternative cell differentiation. However, there has been increasing evidence of hematopoietic plasticity and cell lineage conversion, particularly during leukemogenesis ([@bib8], [@bib19], [@bib21], [@bib41]). The transcription factors C/EBPα and C/EBPβ are potent inducers of myelomonocytic genes in heterologous cell types ([@bib35]), and the experimental conversion of lymphoid cells to myeloid cells modulated by both C/EBPs has highlighted their lympho-myeloid transdifferentiation potential ([@bib20]).

The C/EBP family members C/EBPα, C/EBPβ, C/EBPδ, and C/EBPε are expressed in myeloid cells ([@bib7], [@bib46]). Loss-of-function studies in genetically modified mice suggested combinatorial and partially redundant functions of C/EBPs in myelopoiesis ([@bib56]). Knockout studies showed that deletion of *Cebpa* has the strongest impact on myelopoiesis, resulting in an almost complete loss of neutrophils and impaired development of granulocyte-macrophage progenitor (GMP) cells ([@bib61], [@bib62]). However, cytokines could compensate for the lack of *Cebpa* by the concomitant activation of *Cebpb*, and genetic replacement of *Cebpa* with *Cebpb* in the *Cebpa* locus compensates for the *Cebpa* requirement in hematopoiesis and liver functions ([@bib6], [@bib22], [@bib25]). Individual deletions of C/EBPβ, δ, and ε evoke milder and gene-specific phenotypes, such as susceptibility to infections, failure of emergency granulopoiesis, impaired cytokine production, and partial granulocyte deficiency that is intensified by compound C/EBP gene deletions. For example, compound *Cebpb*/*Cebpe* deletion mutants display impaired granulopoiesis, defective macrophage functions, and a disrupted innate immune regulatory gene expression network, confirming the compensatory and redundant functions of the C/EBPs ([@bib1], [@bib22], [@bib31], [@bib54], [@bib60]).

C/EBPα can stimulate the transdifferentiation of B and T cells and, together with PU.1, even fibroblasts into macrophages ([@bib4], [@bib17], [@bib35], [@bib59]). Conversion of B cells into inflammatory-type macrophages occurs rapidly after C/EBP expression, with high efficiency and through a direct route ([@bib4], [@bib14], [@bib59]). An experimental transdifferentiation system based on an estrogen-responsive, conditional C/EBPα protein in the *v-H-ras*-transformed pre-B cell line HAFTL1 ([@bib23]) has served as a tool to examine the mechanistic aspects of lympho-myeloid lineage conversion, including alterations of chromatin occupancy, gene expression kinetics, non-coding RNA expression, and DNA methylation ([@bib3], [@bib14], [@bib26], [@bib28], [@bib42], [@bib43], [@bib57]).

We recently found that structural alterations and post-translational modification sites of C/EBPβ may determine the path of transdifferentiation of primary progenitor B cells toward distinct myeloid cell fates (including granulocytes and dendritic cells), suggesting that epigenetic instructions beyond the inflammatory macrophage cell fate are encoded in the C/EBP structure and could account for cell-type specification ([@bib52]). This observation has prompted us to compare the lineage conversion capacity of all transactivator C/EBP family members and to develop a lympho-myeloid transdifferentiation system that is amenable to targeted mouse genetics and cell-culture manipulation.

In this study, we generated murine v-Abl-immortalized B cells from wild-type and genetically altered mice to compare the lympho-myeloid transdifferentiation potential of the C/EBP family members C/EBPα, C/EBPβ, C/EBPδ, and C/EBPε. Our data showed that C/EBPβ and C/EBPε readily induce a granulocytic fate in addition to macrophage formation. Granulocytic conversion largely depended on transgene dosage. In addition, efficient transdifferentiation required endogenous *Cebpa*/*Cebpb*. Importantly, applying selective pressure on immortalized B cells expressing C/EBPβ by depriving β-mercaptoethanol resulted in the rapid extinction of B cells and massive expansion of stable myeloid cells. These myeloid progenitors displayed bipotential GMP-like properties and continuously produced macrophages and granulocytes. This process could suggest a link between C/EBP-induced lympho-myeloid lineage switch and a B cell-derived leukemic myelomonocytic GMP-like phenotype ([@bib49]).

Results {#sec2}
=======

Transdifferentiation Potential of Various C/EBP Family Members {#sec2.1}
--------------------------------------------------------------

v-Abl-immortalized pre-B cells derived from primary mouse bone marrow cells (hereafter termed ''B cells'') were used to assess the ability of individual C/EBP family members to induce B-lymphoid to myeloid transdifferentiation ([@bib45], [@bib47]). pMSCV-based retroviral expression vectors (MIG) encoding full-length C/EBPα-, C/EBPβ-, C/EBPδ-, or C/EBPε-IRES-EGFP were constructed ([Figure 1](#fig1){ref-type="fig"}A). Transgene expression was confirmed in the retrovirus-packaging cell line ([Figure S1](#mmc1){ref-type="supplementary-material"}A). As shown in [Figure 1](#fig1){ref-type="fig"}B, each C/EBP family member could induce expression of the myeloid marker CD11b (Mac-1) and caused the transdifferentiation of B cells into CD11b^+^CD19^dim^ myeloid cells. Additional myeloid surface markers indicative of dendritic cells (CD11c^+^), macrophages (CD115^+^), or granulocytes (Ly-6G^+^), were included to assess myeloid subsets in the CD11b^+^ population ([Figure S1](#mmc1){ref-type="supplementary-material"}B). While no CD11c^+^ cells were found, a fraction of transdifferentiated cells showed upregulated CD115 (MCSF-R), a macrophage marker and C/EBP target gene. A CD11b^+^Ly-6G^+^ population, characteristic of granulocytes, was detected with C/EBPε expression, consistent with observations of strong mRNA expression of C/EBPε in bone marrow-derived granulocytes ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). C/EBPβ expression also caused the formation of a CD11b^+^Ly-6G^+^ population after prolonged transdifferentiation for 6 days, whereas C/EBPα and C/EBPδ expression did not ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B). Interestingly, the expression of Ly-6G and CD115 appeared to be mutually exclusive, as no double-positive cells could be detected, indicating a stringent mechanism of cell-fate decision ([Figure 1](#fig1){ref-type="fig"}C). Cytospin preparations of GFP^+^ cells confirmed that all C/EBPs stimulated the formation of myeloid cells with monocyte/macrophage features ([Figure 1](#fig1){ref-type="fig"}D). The C/EBPβ- and C/EBPε-transdifferentiated cell population contained small cells with segmented or indented nuclei, strongly resembling bone marrow-derived granulocytes and suggesting that C/EBPε or C/EBPβ may induce granulocyte/macrophage (G/M) cell fates. Transdifferentiation into granulocytes by C/EBPβ and C/EBPε was not restricted to the v-Abl B cell system, but also occurred in the fetal liver-derived *H-ras*-transformed HAFTL1 pre-B cell line ([Figure S1](#mmc1){ref-type="supplementary-material"}D) ([@bib4]). These findings suggest that all the tested C/EBP transcription factors could cause the conversion of B cells to myeloid cells and that C/EBPβ and C/EBPε could stimulate macrophage and granulocyte transdifferentiation of B cells.

Quantitative gene expression analysis was performed by NanoString hybridization 1 day after transduction with individual C/EBPs, at the earliest emergence of GFP-positive cells ([Figures 2](#fig2){ref-type="fig"}A and 2B; [Table S1](#mmc2){ref-type="supplementary-material"}). A predefined mouse immunology code set covering 547 probes, including key transcription factors, was used. Genes with 2-fold altered expression levels, compared with empty vector-transduced B cell controls, were considered. As shown in [Figures 2](#fig2){ref-type="fig"}A and 2B, all C/EBPs upregulated and downregulated a core set of 22 and 12 genes, respectively. Each C/EBP family member also displayed additional and partial overlapping regulatory specificity. The core transdifferentiation signature of 22 upregulated genes included myeloid factors, such as *Csf1r*, *Csf2rb*, *Fcgr1*, and *Gfi1*, and several chemokine CC-family members ([Figure 2](#fig2){ref-type="fig"}C). The 12 downregulated genes included lymphocyte genes, such as *Il7r*, *Cd2*, and the *Rag* genes ([Figure 2](#fig2){ref-type="fig"}D). These data suggest that C/EBPα, β, δ, and ε likely suppress the B cell program and induce lympho-myeloid conversion.

Deletion of Endogenous *Cebpa* and *Cebpb* Impairs Transdifferentiation but Has No Impact on Cell-Type Outcome {#sec2.2}
--------------------------------------------------------------------------------------------------------------

As previously reported by [@bib4] and shown in [Figure S2](#mmc1){ref-type="supplementary-material"}A, activation of conditional C/EBPα-ER induced endogenous *Cebpb* and *Cebpd* gene expression in HAFTL1 B cells. We induced myeloid transdifferentiation via C/EBPε expression in HAFTL1 cells and analyzed endogenous C/EBPα and C/EBPβ protein expression. Interestingly, the expression of C/EBPε also led to a marked upregulation of endogenous C/EBPα after 16 hr, while only low levels of C/EBPβ were detected. However, after 24 hr, C/EBPβ protein expression increased while C/EBPα expression was diminished. A surge of C/EBPα and C/EBPβ expression was observed after 120 hr, indicating crosstalk between transgenic and endogenous C/EBPs during transdifferentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

Synergistic collaboration between C/EBP family members was previously described as a key element to specify myeloid differentiation ([@bib1]). To examine the contribution of endogenous C/EBPs to lympho-myeloid transdifferentiation, we treated B cells generated from a homozygous *Cebpa*^f/f^;*Cebpb*^f/f^ mouse with cell-permeable Cre-recombinase to generate double-knockout derivatives ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Verified Cebpa^Δ/Δ^;Cebpb^Δ/Δ^ double-knockout B cell clones were designated as "B-DKO" ([Figure S2](#mmc1){ref-type="supplementary-material"}D).

B-DKO cells or isogenic controls (not treated with Cre-recombinase) were infected with the G/M-transdifferentiation proficient retroviral constructs that co-expressed C/EBPβ and GFP (MIG) or C/EBPε and BFP (MIB) ([Figures 3](#fig3){ref-type="fig"}A and 3B). GFP^+^BFP^+^ gated cell populations, indicative of C/EBPβ and C/EBPε expression, were analyzed ([Figure 3](#fig3){ref-type="fig"}C). Deletion of endogenous *Cebpa* and *Cebpb* strongly impaired transdifferentiation induced by C/EBPε or C/EBPβ after 4 days, in comparison with isogenic controls ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E). Transdifferentiation efficacy in C/EBPε-expressing B-DKO cells could be partially rescued by retroviral co-expression of C/EBPβ. These data suggest synergistic effects between endogenous and exogenous C/EBPs during transdifferentiation ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E).

Comparison of gene expression in C/EBPε-transduced wild-type or B-DKO cells revealed genes that were dependent on endogenous *Cebpa* and *Cebpb* ([Figure S2](#mmc1){ref-type="supplementary-material"}F and [Table S1](#mmc2){ref-type="supplementary-material"}). The list of refractory genes included *Csf1r*, *Fcgr1*, *Itgam* (CD11b), and the transcription factor *Gfi1*, known to promote granulocyte differentiation. These genes represent important myeloid cell factors, and failure of induction may explain the impaired transdifferentiation ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}E). In addition, *Pax5* or *Pou2f2* (Oct-2) were refractory to downregulation, which could contribute to the persistence of the B cell phenotype ([Figure S2](#mmc1){ref-type="supplementary-material"}G and [Table S1](#mmc2){ref-type="supplementary-material"}).

To determine whether the G/M cell-type outcome was affected by deletion of endogenous *Cebpa* and *Cebpb*, we analyzed C/EBPε-transdifferentiated GFP^+^CD11b^+^ cells for Ly-6G or CD115 surface marker expression after 7 days of culture. Comparison of transdifferentiated B-DKO and control cells did not reveal differences in the frequency of Ly-6G^+^ versus CD115^+^ cells in the CD11b^+^-gated cell population ([Figure 3](#fig3){ref-type="fig"}D), suggesting that the continuously expressed transgene product but not endogenous *Cebpa* and *Cebpb* predominantly affected myeloid cell lineage choice.

C/EBP Dosage and Granulocyte-Macrophage Lineage Choice {#sec2.3}
------------------------------------------------------

Transcription factor dosage is an important determinant in hematopoietic lineage choice ([@bib9], [@bib11], [@bib10], [@bib13], [@bib33], [@bib44], [@bib48]). We therefore examined how the level of C/EBP transgene expression would alter lympho-myeloid cell fate. As shown in [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B, GFP intensity directly correlated with retroviral C/EBP protein expression and enabled us to examine transcription factor dosage effects on lympho-myeloid transdifferentiation. Based on increasing GFP intensity, C/EBPβ-transduced B cells were divided into six fractions, GFP1--6 ([Figure 4](#fig4){ref-type="fig"}A). Macrophage and granulocyte surface marker analysis of the CD11b^+^ cells revealed a bipartite profile when all GFP^+^ cells were included in the analysis (as in [Figure 1](#fig1){ref-type="fig"}C). As shown in [Figures 4](#fig4){ref-type="fig"}B and 4C, the distribution of CD11b^+^Ly-6G^+^ versus CD11b^+^CD115^+^ shifted according to the GFP intensity. GFP^dim^ fractions were preferentially CD11b^+^CD115^−/+^ and Ly-6G^−^. The CD11b^+^Ly-6G^+^ cell population expanded with increasing GFP intensity, while the CD11b^+^CD115^+^ cell fraction diminished. The fraction with the highest GFP intensity (GFP6) consisted mostly of CD11b^+^Ly-6G^+^ cells ([Figures 4](#fig4){ref-type="fig"}B and 4C). Cytospin preparations of GFP^dim^- and GFP^high^-sorted cells showed that the GFP^dim^ fraction consisted of large cells, characteristic of monocyte/macrophages, while the GFP^high^ fraction contained cells with indented and segmented nuclei---typical features of mature granulocytes ([Figure 4](#fig4){ref-type="fig"}D). Finally, B cells transduced with C/EBPε were separated by flow cytometry according to their GFP intensity 24 hr post infection. Six days later, cell-surface marker expression analysis indicated that the GFP^high^ cells were enriched for Ly-6G^+^ versus CD115^+^ cells when compared with the GFP^+^ culture. These data indicate a prospective cell-type outcome according to the initial C/EBP dosage ([Figure 4](#fig4){ref-type="fig"}E). To further exclude artifacts produced by the bicistronic C/EBP-IRES-EGFP MIG constructs, we examined the dosage effect using retroviral vectors with direct C/EBPε-GFP fusion. As shown in [Figure S3](#mmc1){ref-type="supplementary-material"}C, higher GFP intensity correlated with the G/M surface marker profile. Taken together, these findings show that the dosage of C/EBPβ or C/EBPε transcription factors determines granulocyte versus macrophage cell-fate outcome during lympho-myeloid transdifferentiation.

Long-Term Proliferating C/EBPβ-Lympho-Myeloid Progeny Display a GMP-like State and Spontaneously Differentiate into Granulocytes and Macrophages {#sec2.4}
------------------------------------------------------------------------------------------------------------------------------------------------

To assess the proliferation and lineage-forming capacity of C/EBPβ-transdifferentiated B cells, we aimed to establish a stably converted B cell line. After the removal of β-mercaptoethanol, an essential culture supplement for B cell maintenance, all B cells perished within a few days in C/EBPβ-transduced and empty vector-transduced cells. In contrast to the controls, however, proliferating GFP^+^ cells emerged from C/EBPβ-transduced B cells within 2 weeks after infection. Comparison of surface marker expression after 8 days and 6 weeks of cell culture showed that the long-term proliferating cells maintained both macrophage and granulocyte differentiation potential ([Figures 5](#fig5){ref-type="fig"}A and 5C). Cytospin preparations from CD11b^+^Ly-6G^+^ and CD11b^+^CD115^+^ sorted cells resembled typical granulocytes and macrophages, respectively ([Figures 5](#fig5){ref-type="fig"}B and 5D). Genotyping of rearranged immunoglobulin heavy chain (IgH) locus of C/EBPβ-transduced cells ruled out the possibility of a contamination with myeloid remnants from initiating cultures ([Figure 5](#fig5){ref-type="fig"}E). Immunoblot analysis showed that transgenic C/EBPβ protein is present and that endogenous C/EBPβ protein isoforms are also upregulated in transdifferentiated cells ([Figure 5](#fig5){ref-type="fig"}F). In addition, C/EBPβ-transduced cells grew in a semi-adherent fashion and showed irregular morphological features typical of myeloid progenitor cells, in contrast to round, refractile B cells. Upon treatment with recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) the proliferation rate decreased and cells became adherent, large, and motile, resembling activated macrophages and suggesting that the transdifferentiated cells respond to myeloid signaling pathway activation ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B).

The G/M bilineage phenotype of the transdifferentiated cells was maintained during more than 6 months of continuous cell culture. Nevertheless, C/EBPβ may stimulate B cells to transdifferentiate into distinct G and M progenitors either directly or through a common GMP cell type. To distinguish between these possibilities, we seeded 4,500 of the stably transdifferentiated cells into semi-solid medium to derive colonies from single cells. Approximately 40--70 colonies were obtained in a single experiment. Individual GFP^+^ colonies were inspected from day 6 to day 18 and displayed a compact core and a periphery of larger motile, oval cells, reminiscent of colony-forming unit GM colonies ([Figure 5](#fig5){ref-type="fig"}G). Two colonies were isolated and propagated in liquid culture and both displayed a Ly-6G^+^ and CD115^+^ phenotype indicative of GMP-like potential ([Figure 5](#fig5){ref-type="fig"}H, result for one clone is shown). Subsequent recloning of one of the isolates in semi-solid medium resulted in stably growing secondary subclones (cloning efficiency between ∼4% and 6%) and persistence of the GMP-like phenotype of all 17 subclones examined, as shown in [Figure S5](#mmc1){ref-type="supplementary-material"}.

We conclude that C/EBPβ-induced lympho-myeloid conversion confers a selective advantage by abrogating the dependence on B cell survival conditions. These C/EBPβ-converted cells acquire cytokine-independent long-term proliferation capacity and a robust GMP-like potential.

Discussion {#sec3}
==========

Transcription factor-mediated conversion of one cell type into another is an important avenue by which we can advance our understanding of instructive mechanisms of cellular lineage commitment and differentiation. The primary B cells immortalized by v-Abl provide an experimental system to combine B cell mouse genetics and ectopic gene expression for the exploration of progenitor biology, lympho-myeloid lineage plasticity, maintenance of cell identity, and regulatory mechanisms of myeloid lineage commitment.

Experimental transdifferentiation of B cells by ectopic expression of conditional C/EBPα has shed light on the molecular dynamics of the conversion of lymphoid cells into inflammatory macrophages ([@bib4], [@bib14], [@bib28], [@bib29], [@bib42], [@bib43], [@bib57], [@bib59]). However, lympho-myeloid transdifferentiation may not be restricted to activated macrophages but may yield other myeloid cell types depending on the C/EBP structure and post-translational modification pattern ([@bib52]). Here, we assessed the lympho-myeloid transdifferentiation potential of C/EBP α, β, δ, and ε in primary v-Abl-immortalized B cells. Our data show that v-Abl B cells represent a robust in vitro system for experimental cell lineage switch and may also be used for targeted murine genetics and in vitro genetic manipulation at the B cell stage.

Lineage conversion could be achieved using any of the four C/EBP members, revealing a common gene signature, and their common potential to extinguish B cell identity and induce the myeloid cell fate. C/EBPβ and C/EBPε induced granulocytic differentiation in addition to monocytic transdifferentiation. Granulopoietic capacity of C/EBPβ has previously been documented in emergency granulopoiesis ([@bib22]) and by restoring *Cebpa* deficiency ([@bib25]). The lack of granulopoietic transdifferentiation potential of C/EBPα was surprising and has been discussed previously ([@bib59]), because C/EBPα induced granulocyte differentiation in a myeloid progenitor cell line ([@bib40], [@bib53]). Although we do not know why C/EBPα and C/EBPδ fail to induce granulocyte formation, the strong proliferation arrest elicited by C/EBPα could account for the failure of granulocytic conversion. On the other hand, our data may also raise the possibility that some of the functions of C/EBPα reported in established progenitor cell lines may depend on the activation of endogenous C/EBPβ. Nevertheless, the v-Abl B cell system could be useful to resolve quantitative and qualitative C/EBP functions and help uncover mechanisms of lineage specification, e.g., by C/EBP domain-swap experiments and mutational analysis.

Our findings support the concept that subtle variations in transcription factor levels have an impact on hematopoietic cell lineage decisions. In addition to transcription factor dosage, specificity and functional redundancy play major roles; high levels of C/EBPβ or C/EBPε consistently increased the granulocyte over macrophage ratio. The exact interplay between C/EBP quantity and qualitative specificity remains to be explored, but is likely similar to graded PU.1 expression that has an impact on lympho-myeloid specification by occupancy of low-affinity binding sites only at high transcription factor concentrations ([@bib10], [@bib38]). Relative expression levels of PU.1 and C/EBPα are also key determinants in granulocyte versus macrophage specification. Higher PU.1 levels promote macrophage differentiation, while higher C/EBPα levels lead to granulopoiesis ([@bib9], [@bib33]). Therefore, less accessible "granulocytic genes" may require higher C/EBP concentrations in addition to other features of C/EBPβ and C/EBPε proteins.

Activation of endogenous C/EBP genes and impaired lineage conversion after their removal suggests that autoregulatory loops are involved in the kinetics of lineage conversion ([@bib4], [@bib32]). However, deletion of endogenous C/EBPα and C/EBPβ appears to affect the conversion efficiency but not the lineage outcome, suggesting a dominant and distinguished qualitative role for the constitutively expressed C/EBP transgene.

Leukemia with indifferent or promiscuous lineage association is frequently resistant to standard chemotherapy and may show changed lineages during relapse ([@bib15], [@bib18], [@bib34]). Inter-myeloid and lympho-myeloid lineage ambiguity therefore emerges as an important pathological entity ([@bib21], [@bib50]). It is therefore conceivable that switching lineages reflect an epigenetic selection process in leukemogenesis associated with gain-of-function survival and proliferation capacity ([@bib21], [@bib24], [@bib41]). Our experimental data provide direct evidence that enhancing the selective pressure on B cells by removal of β-mercaptoethanol strongly promotes C/EBPβ-induced lympho-myeloid converts that remained immortalized and highly proliferative. We therefore conclude that cancerous B cells may escape from hostile conditions by lineage conversion through C/EBPβ activation. Furthermore, B cells could profit from lineage-foreign survival signals by aberrant expression of growth factor receptors, such as CSF1-R, a target gene of C/EBPβ ([@bib30]). Various C/EBP translocations have been associated with B cell-derived leukemia, implying their cancer-supporting function. However, the role played by transdifferentiation remains unknown ([@bib2], [@bib5], [@bib49], [@bib58]). Strikingly, DNA demethylation and upregulation of C/EBPα was suspected to be involved in lineage switching during leukemia progression ([@bib49]). In addition to pre-B cell lymphoma, v-Abl retroviral infection of murine bone marrow cells also evoked a chronic myeloid leukemia-like disease that involved immunoglobulin rearrangements ([@bib27]).

In a recent study, pulsed C/EBPα expression was shown to induce a GMP-like state according to gene expression and chromatin accessibility data. However, during prolonged exposure only a macrophage fate was consolidated ([@bib12]). Remarkably, the stable C/EBPβ B cell converts reported here resembled self-renewing bipotential GMP progenitors that were responsive to GM-CSF but not dependent on cytokine signaling, and stably retained G/M differentiation potential. In the absence of cytokines, expression of macrophage- and granulocyte-specific markers emerged in a mutually exclusive fashion. These data suggest the involvement of C/EBPβ in maintenance, commitment, or both at the GMP stage.

The cytokine-independent, self-renewing, spontaneously differentiating GMP-like cells present a valuable experimental tool for the study of determinants of granulocyte versus macrophage specification by genetic manipulation and screening approaches. In addition, maintenance of the transdifferentiation capacity of the v-Abl B cells establishes a sound basis for using targeted genetic mouse models to examine signaling pathways and other instructive cues of cell specification. The fact that v-Abl B cells are amenable to DNA transfection permits experimental alteration at the B cell stage, such as stable transfection, gene deletion, or chromosomal engineering, and is an important technical advance in overcoming the hurdle of difficult genetic manipulation of myelomonocytic cells.

In summary, we present a robust in vitro lympho-myeloid transdifferentiation system to study determinants of lineage promiscuity, GMP progenitor biology, and macrophage versus granulocyte cell-fate decisions. In addition, our findings lend experimental evidence to lympho-myeloid transdifferentiation processes as a trait of lineage ambiguity in leukemia progression.

Experimental Procedures {#sec4}
=======================

Expression Constructs {#sec4.1}
---------------------

C/EBP genes were inserted into pMSCV-IRES-EGFP (MIG) or pMSCV-IRES-BFP (MIB) retroviral vectors using XhoI/EcoRI restriction sites. C/EBPs lacking stop codons were cloned in-frame with the EGFP open reading frame and inserted into pMSCV for C/EBP-GFP fusion construct. Expression vectors encoding C/EBPα p42 isoform and C/EBPβ LAP^∗^ isoform were described previously ([@bib52]). Murine C/EBPδ was isolated from pMEX-mC/EBPδ (a gift from Dr. E Sterneck). Codon-optimized human C/EBPε p32 isoform was commercially synthesized (MWG-Biotech) and subcloned from pEX-A2 into MIG or MIB using EcoRI sites flanking C/EBPε. The v-Abl-expressing pMSCV vector was a gift from Dr. F Melchers ([@bib36]). For production of infectious supernatants the retroviral packaging cell line Plat-E was used. Infectious supernatants were collected 48 hr and 72 hr after transfection.

Generation of v-Abl-Transformed B Cells {#sec4.2}
---------------------------------------

Bone marrow cells were isolated from the femur and tibia of 8- to 9-week-old *Cebpa*^f/f^-crossed ([@bib62]) and *Cebpb*^f/f^-crossed ([@bib51]) *Cebpa*^f/f^;*Cebpb*^f/f^ mice and C57BL/6J wild-type controls. These mice were maintained and handled in compliance with protocols approved by the institutional Animal Care and Use Committee. After erythrolysis, bone marrow cells were transduced with v-Abl-expressing retroviral supernatants and 8 μg/mL hexadimethrine bromide in complete DMEM (10% fetal calf serum (FCS), 10 mM HEPES, and penicillin/streptomycin (Gibco)) supplemented with 50 μM β-mercaptoethanol. Bone marrow cells were washed on the following day and medium was changed every other day. A stable cell line with a pre-B cell-like phenotype (CD19^+^, c-kit^−^, CD25^+^, IgM^−^) emerged after 4 weeks of culture. For *loxP* site recombination, 5 × 10^5^ B cells were washed three times in serum-free DMEM and incubated with purified TAT-Cre protein (50 μg/mL; a gift from Dr. K Rajewsky) in serum-free DMEM at 37°C for 45 min ([@bib37]). The cells were then washed and cultured for 24 hr and seeded subsequently as single-cell clones (by fluorescence-activated cell sorting (FACS)) into 96-well plates. Deletion of the *Cebpa* and *Cebpb* genes was checked by PCR to identify double-knockout clones. Primer sequences used are shown in [Table S2](#mmc1){ref-type="supplementary-material"}.

Cell Lines {#sec4.3}
----------

The monocytic/macrophage Raw264.7 cell line was cultured in complete DMEM. The fetal liver-derived pre-B cell line HAFTL1 was cultured in complete RPMI-1640 (10% FCS, 10 mM HEPES, penicillin/streptomycin (Gibco)) supplemented with 50 μM β-mercaptoethanol ([@bib39]). The HAFTL1-derived C10 clone (a gift from Dr. T Graf) containing a C/EBPα-ER_IRES_GFP transgene was cultured in complete phenol red-free RPMI-1640 (10% charcoal-stripped FCS (HyClone), 10 mM HEPES, penicillin/streptomycin (Gibco)) supplemented with 50 μM β-mercaptoethanol ([@bib4]). Transdifferentiation of C10 cells was induced with 200 nM hydroxytamoxifen (Sigma). 293T-derived Plat-E line (Cell Biolabs) was used for packaging.

Retroviral Transduction {#sec4.4}
-----------------------

v-Abl-generated stable B cells or HAFTL1 cells (2 × 10^5^/12-well or 1 × 10^6^/6-well) were mixed with freshly prepared retroviral supernatants (1/3 of total volume) in complete medium supplemented with 8 μg/mL hexadimethrine bromide and 50 μM β-mercaptoethanol. Cells were centrifuged at 1,000 rpm without brakes for 10 min at room temperature and incubated overnight. Infected cells were washed and processed for flow cytometry or replated in 6-well plates (BD Falcon). For the generation of the long-term proliferating transdifferentiated cells, β-mercaptoethanol supplementation was omitted after 24 hr. Half of the medium was changed every other day.

Flow Cytometry {#sec4.5}
--------------

For flow cytometry or cell sorting, cells were transferred to 15-mL tubes and washed in cold buffer (2% FCS, 2 mM EDTA in PBS). Before antibody labeling, cells were incubated with Fc-Block (1:200, anti-CD16/32 antibody; 2.4G2, BD Pharmingen) for 10 min at 4°C and washed. Cells were stained in buffer with (1:100) fluorescently labeled antibodies against CD11b (clone M1/70, BD Pharmingen), CD11c (clone N418, Biolegend), CD115 (clone AFS98, eBioscience), CD19 (clone 1D3, BD Pharmingen), and Ly-6G (1A8, Biolegend) for 30 min at 4°C in the dark. 7-AAD (BD Pharmingen) was added before measurement to exclude dead cells. Analysis was performed on LSRFortessa and sorting on FACSAria II or III (BD Pharmingen). Unstained, empty vector-transduced cells or fluorescence-minus-one staining setups served as controls.

PCR {#sec4.6}
---

Total RNA was prepared using TriPure (Roche) following the manufacturer\'s instructions. DNA contamination was removed by DNase I treatment (Roche). For standard cDNA synthesis the RevertAid First Strand Synthesis Kit (Thermo Scientific) was used. Ten nanograms of cDNA was applied to PCR according to the MangoTaq kit protocol (Bioline). PCR reaction was subjected to 94°C for 3 min and 27 cycles of 94°C for 30 s, 56°C for 30 s, 72°C for 30 s, and a final extension step at 72°C for 5 min on a Mastercycler Pro (Eppendorf). For detection of D~H~-J~H~ IgH rearrangements, DNA was prepared as described by [@bib55] and subjected to PCR conditions as reported by [@bib16], using the combination of primers DQ52 FW1, DFS FW2, and JH4A RV. *Cebpa* and *Cebpb* genotypes were assessed using "-flox" or "-Δ" primer pairs, respectively.

Immunoblotting {#sec4.7}
--------------

Total protein lysates were prepared by incubation of snap-frozen cell pellets with lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 1 mM EDTA, 10% glycerol, and proteinase inhibitor cocktail \[Roche\] in H~2~O) for 30 min on ice. After centrifugation protein concentration was measured in supernatants using Pierce Reagent (Thermo Scientific). Protein lysates were subjected to electrophoresis and transferred to a nitrocellulose membrane on the Trans-Blot Turbo System (Bio-Rad). Specific protein signals were detected by incubation with antibodies against C/EBPα (14AA, Santa Cruz Biotechnology), C/EBPβ (C-19, Santa Cruz), C/EBPδ (C-22, Santa Cruz), C/EBPε (C-22, Santa Cruz), GFP (7.1/13.1, Roche), and ACTB (AC-15, Sigma).

NanoString Analysis {#sec4.8}
-------------------

Total RNA from freshly FACS-enriched cells or cell cultures was prepared and quality checked on a 2100 Bioanalyzer (Agilent Technologies). Detection of mouse protein-coding transcripts was performed using a predefined panel (GXA-MIM1-12, nCounter), containing 547 probes against immunology-related mRNAs and 14 probes against housekeeping genes (*G6pdx*, *Hprt*, *Gapdh*, *Alas1*, *Oaz1*, *Sdha*, *Rpl19*, *Eef1g*, *Tbp*, *Ppia*, *Polr2a*, *Gusb*, *Tubb5*, and *Polr1b*) for normalization. Primary data were processed using default settings of the nSolver software. Genes were defined as "upregulated" or "downregulated" if normalized expression values were increased or decreased at least 2-fold compared with empty vector-transduced controls.

Statistical Analysis {#sec4.9}
--------------------

Processed data were visualized using GraphPad Prism software (Version 5.0a). Error bars represent the SEM. Hypothesis testing was performed from at least three independent experiments using the t-test function (two-tailed) in Rstudio (R version 3.2.1, R Foundation). p Values of \<0.05 were defined as significant and p \< 0.01 highly significant.
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![C/EBPα, β, δ, and ε Transdifferentiate B Cells to Myeloid Cells\
(A) pMSCV-based vectors containing an internal ribosomal entry site (IRES) and EGFP (MIG) marker used for retroviral transduction. Full-length open reading frames of *Cebpa*, *Cebpb*, *Cebpd*, or *Cebpe* were inserted upstream of the IRES element. Empty vector (MIG) served as control.\
(B) Flow cytometric analysis of GFP^+^-infected B cells 4 days after transduction with individual C/EBPs.\
(C) Analysis of granulocyte (Ly-6G) and macrophage (CD115) cell-surface markers in GFP^+^CD11b^+^ transdifferentiated cells 6 days after transduction.\
(D) May-Grünwald staining of GFP^+^-sorted B cells 4 days after transduction. Arrows indicate cells with typical macrophage morphology and arrowheads mark granulocyte-like cells. Primary bone marrow (BM) and sorted granulocytes (Gr) were used as references (far right).\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Transdifferentiation Core Gene Signatures of B Cells Induced with C/EBP Family Members\
Quantification of mRNA from GFP^+^-sorted B cells 24 hr after transduction with individual C/EBPs. Venn diagram of (A) upregulated and (B) downregulated genes, compared with empty vector (MIG) control. Overlapping core signatures of (C) 22 upregulated or (D) 12 downregulated genes. Key myeloid (in C) and lymphoid (in D) genes are shown in bold. The fold change (FC) relative to empty vector (MIG)-transduced B cells is shown. See also [Table S1](#mmc2){ref-type="supplementary-material"}.](gr2){#fig2}

![Endogenous *Cebpa* and *Cebpb* Promote Transdifferentiation but Do Not Affect Lineage Outcome\
(A) pMSCV-based vectors for the expression of C/EBPβ linked to EGFP marker or C/EBPε linked to BFP. Empty vectors (MIG/MIB) were used as controls.\
(B) *Cebpa*^Δ/Δ^;*Cebpb*^Δ/Δ^ or isogenic control B cells (*Cebpa*^f/f^;*Cebpb*^f/f^) were transduced with combinations of the vectors shown in (A).\
(C) The GFP^+^BFP^−^ fraction (top panels), GFP^−^BFP^+^ fraction (middle panels), and GFP^+^BFP^+^ fraction (bottom panels) were individually analyzed for myeloid (CD11b) and B cell (CD19) markers by flow cytometry after 4 days.\
(D) *Cebpa*^Δ/Δ^;*Cebpb*^Δ/Δ^ B cells and isogenic controls were transduced with C/EBPε, GFP^+^-sorted after 24 hr, and recultured. Flow cytometric analysis of granulocyte (Ly-6G^+^) and macrophage (CD115^+^) cell fractions in GFP^+^CD11b^+^-gated populations 7 days after transduction.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![C/EBPβ Transgene Dosage Affects Macrophage versus Granulocyte Lineage Outcome\
(A) Data binning of C/EBPβ-transduced B cells according to GFP intensity (GFP1--6).\
(B) Flow cytometric analysis of GFP1--6 bins (CD11b + gated) 6 days after transduction.\
(C) Quantification from five independent experiments. Data are presented as mean ± SEM.\
(D) Cytospin preparation and May-Grünwald staining of GFP^dim^- and GFP^high^-sorted C/EBPβ-transduced B cells at day 7. Arrows indicate macrophage and arrowheads granulocyte-like cells.\
(E) B cells were transduced with C/EBPε, sorted after 24 hr as GFP^+^ or GFP^high^, and recultured. Flow cytometric analysis of granulocyte (Ly-6G^+^) versus macrophage (CD115^+^) markers in GFP^+^CD11b^+^-gated populations 6 days post sorting.\
See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Long-Term Proliferating GMP-like Cells Derived from C/EBPβ-Transduced B Cells\
(A) *Cebpa*^f/f^;*Cebpb*^f/f^ B cells transduced with C/EBPβ or vector control (MIG), sorted after 24 hr, and recultured. Flow cytometric analysis of myeloid surface markers was performed after 6 days. Gating strategy is indicated by arrows.\
(B) May-Grünwald staining of macrophage (CD11b^+^CD115^+^) or granulocyte (CD11b^+^Ly-6G^+^) marker-sorted C/EBPβ-transduced cells from (A) and GFP^+^-purified empty vector (MIG)-transduced cells as control.\
(C and D) Flow cytometry analysis (C) and May-Grünwald staining (D) according to (A) and (B) of non-purified C/EBPβ-transduced cells 6 weeks after removal of β-mercaptoethanol.\
(E) Analysis of immunoglobulin heavy chain (IgH) rearrangement of long-term C/EBPβ-transduced cells or MIG-transduced controls. Monocytic Raw264.7 (Mph) cells served as a control for IgH germ line (Gl) configuration.\
(F) Immunoblot analysis of C/EBPβ from protein lysates of long-term C/EBPβ- or empty vector (MIG)-transduced B cells. Arrows indicate C/EBP isoforms; asterisk indicates the size of transgene.\
(G) Colony formation from single cells. Phase contrast (top) and fluorescent signal (bottom) micrographs of a C/EBPβ-transdifferentiated B cell colony. Clonogenic growth is shown at days 6 and 18. Magnification of inset area focuses on the border of the colony.\
(H) Flow cytometric characterization of the recultured cell clone derived from (G) using myeloid markers.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}
